Mazdutide (development codes IBI362 and LY3305677) is a synthetic peptide that acts as a dual agonist at the GLP-1 and glucagon receptors. It is based on the mammalian hormone oxyntomodulin and is being developed by Innovent Biologics under licence from Eli Lilly, primarily for the Chinese market. It has reported strong weight-loss and glycaemic results in Phase 2 and Phase 3 (DREAMS) trials.

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Popular compounds

Research resources

Certificates of Analysis

What is Mazdutide? The Research Guide to the GLP-1/Glucagon Dual Agonist

Q: Is mazdutide FDA approved?

No. As of 2026 mazdutide is not approved by the FDA, EMA or MHRA. It is furthest along in China, where Innovent has pursued regulatory submission for obesity and type 2 diabetes based on the DREAMS Phase 3 program. Outside approved indications and markets it is an investigational compound only.

Q: What weight loss did mazdutide show in trials?

In the DREAMS-1 Phase 3 trial in Chinese adults with overweight or obesity, mazdutide reported mean weight loss in the range of roughly 11 to 14 percent at the higher 6 mg dose over 48 weeks, alongside improvements in liver fat, blood pressure and lipids. Trial outcomes do not transfer outside the trial context.

While the West watches semaglutide and retatrutide, one of the strongest late-stage metabolic peptides is coming through the Chinese pipeline: mazdutide . It is a GLP-1/glucagon dual agonist with Phase 3 data behind it, and it is a genuinely different receptor combination from the drugs most Western researchers know. This is a plain-English guide to what it is, how it works, and how it sits against the rest of the field.

RUO framing throughout. Mazdutide is investigational outside its approved market; any reference material is a laboratory reagent only, not for human consumption or any therapeutic use. Clinical-trial outcomes do not transfer outside the trial context.

The One-Sentence Answer

Mazdutide (development codes IBI362 and LY3305677 ) is a synthetic peptide - based on the natural hormone oxyntomodulin - that activates two receptors at once: GLP-1 and glucagon . It is developed by Innovent Biologics under licence from Eli Lilly, primarily for China.

How Mazdutide Fits Against the GLP-1 Field

The whole modern class is defined by which receptors each molecule hits. Mazdutide's signature is that it swaps GIP for glucagon:

Compound Receptor targets Developer Status Semaglutide GLP-1 only Novo Nordisk FDA approved Tirzepatide GLP-1 + GIP Eli Lilly FDA approved Mazdutide GLP-1 + Glucagon Innovent / Lilly Phase 3 (China-led) Survodutide GLP-1 + Glucagon Boehringer / Zealand Phase 3 Retatrutide GLP-1 + GIP + Glucagon Eli Lilly Phase 3

Mazdutide and survodutide share the same GLP-1/glucagon pairing, and both sit "one receptor short" of retatrutide. The glucagon component is what distinguishes this branch from tirzepatide's GIP branch.

Why the Glucagon Receptor Matters

Adding glucagon-receptor activity changes the metabolic profile in two ways the GLP-1-only and GLP-1/GIP drugs don't emphasise:

Energy expenditure - glucagon-receptor activation increases resting metabolic rate, so the body burns more at baseline rather than only eating less.

Liver fat - the glucagon arm drives hepatic lipid mobilisation, which is why mazdutide and its glucagon-active peers report notable reductions in liver-fat content in trials. This has made the class a focus for MASLD (fatty liver) research as well as obesity.

The trade-off researchers watch for is that glucagon activity can nudge glucose and heart rate, so the GLP-1 arm has to be balanced against it - the peptide is engineered for a specific GLP-1:glucagon potency ratio.

The Trial Landscape: DREAMS and GLORY

Mazdutide's late-stage evidence comes mainly from Innovent's Chinese Phase 3 programs:

GLORY-1 - adults with overweight or obesity; reported clinically meaningful weight loss and metabolic improvement at 48 weeks.

DREAMS - the type 2 diabetes and obesity program used to support regulatory submission in China.

Reported figures at the higher 6 mg dose have landed in the roughly 11-14% mean weight-loss range over about 48 weeks, alongside improvements in HbA1c, blood pressure, lipids and liver fat. Those are strong dual-agonist numbers - below retatrutide's triple-agonist Phase 2 headline (~24%) but competitive within the dual-agonist tier. As always, cross-trial comparison across different populations is not the same as a randomised head-to-head.

Population note. Mazdutide's pivotal data is largely in Chinese cohorts. Baseline BMI and metabolic profiles differ between trial populations, so read the percentages in that context rather than assuming they map one-to-one onto Western trial numbers.

Regulatory Status

Mazdutide is furthest along in China , where Innovent has pursued approval for obesity and type 2 diabetes on the strength of the Phase 3 data. It is not approved by the FDA, EMA or MHRA , and there is no Western approval timeline comparable to the domestic Chinese one. Outside its approved indications and market, it is an investigational compound.

Investigational status. Mazdutide is not approved by the FDA, EMA, MHRA or any Western regulator as of 2026. Any mazdutide reference material outside an approved market or active clinical trial is a research-grade reagent only - not licensed for human consumption, weight-loss application, or any therapeutic purpose. Like all GLP-class agonists it is on the WADA Prohibited List (S2).

The Honest Picture for Researchers

Mazdutide is a real late-stage compound , not a vaporware code - the DREAMS/GLORY Phase 3 data is substantial.

Its mechanism (GLP-1/glucagon) is a distinct, well-motivated branch, sharing the glucagon arm with survodutide and retatrutide.

Its evidence base is China-led , which shapes both the population data and the regulatory geography.

Its Western regulatory status is unambiguous: not approved, research-grade only.

Verification is non-negotiable . An oxyntomodulin-based dual agonist is a complex molecule; only a third-party HPLC COA (Janoshik, Freedom Diagnostics) confirms identity and purity. See how to read a COA.

Frequently Asked Questions

What is mazdutide? Mazdutide (codes IBI362 / LY3305677) is a synthetic peptide that acts as a dual agonist at the GLP-1 and glucagon receptors. Based on the hormone oxyntomodulin, it is developed by Innovent Biologics under licence from Eli Lilly, primarily for China, and has reported strong weight-loss and glycaemic results in Phase 2 and Phase 3 trials.

How does mazdutide differ from retatrutide? It is about receptors. Tirzepatide is GLP-1/GIP. Mazdutide is GLP-1/glucagon - it swaps GIP for glucagon, adding energy-expenditure and liver-fat mechanisms. Retatrutide is the triple agonist hitting all three. Mazdutide shares the glucagon arm with retatrutide but does not add GIP.

Is mazdutide FDA approved? No. As of 2026 it is not approved by the FDA, EMA or MHRA. It is furthest along in China, where Innovent pursued approval for obesity and type 2 diabetes on the DREAMS Phase 3 data. Elsewhere it is investigational only.

What weight loss did mazdutide show in trials? In Chinese Phase 3 trials, the higher 6 mg dose reported roughly 11-14% mean weight loss over about 48 weeks, with improvements in liver fat, blood pressure and lipids. Trial outcomes do not transfer outside the trial context or population.

Where can I buy mazdutide for research? Mazdutide is investigational and not sold by pharmacies outside its approved market. Laboratories that study it source reference material from suppliers that publish a per-batch CoA and label material research use only. Third-party HPLC verification and a batch COA are the key control for any research-grade peptide.

From the Lab - Peptides on LinkedIn & Facebook

Research the GLP-1 Field, Verified.

New-U supplies sealed, independently HPLC-verified research peptides across the metabolic class - each lot COA-backed by Janoshik and Freedom Diagnostics. Research use only, not for human consumption. Investigational compounds, WADA-prohibited in sanctioned competition.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.